News and Press Releases
Press releases
Theralase Technology Proven Effective for the Treatment of Arthritis
Press ReleaseToronto, Ontario – June 29, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain a...
Theralase Researcher Granted Second US Patent for Novel Anti-Cancer Drugs
Press ReleaseToronto, Ontario – June 26, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain a...
Theralase Presents Phosphorescent Photosensitizers at International World Congress
Press ReleaseToronto, Ontario – June 15, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and...
Theralase Presents X-Ray Activation at International World Congress
Press ReleaseToronto, Ontario – June 14, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain a...
Theralase Presents Dosimetry Planning at International World Congress
Press ReleaseToronto, Ontario – June 13, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain a...
Theralase Commences Trading on OTCQX
Press ReleaseToronto, Ontario – June 2, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSX-V: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the d...
Theralase Increases Revenue 23% for 1Q 2017 Financial Statements
Press ReleaseToronto, Ontario – May 30, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the deve...
Theralase Successfully Achieves Primary and Secondary Objectives for First Three Patients Treated Using Anti-Cancer Technology for Bladder Cancer
Press ReleaseToronto, Ontario – May 26, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and th...
Theralase Reports Fiscal Year 2016 Financial Statements
Press ReleaseToronto, Ontario – May 1, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the develop...
Theralase PDT Technology Used to Treat Third Patient for Bladder Cancer
Press ReleaseToronto, Ontario – April 20, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the de...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
